State & Federal Policy / Regulatory Updates

NJATOD’s advocacy letter and supporting brief urging New Jersey agencies to align state OTP regulations and Medicaid policy with the...

This resource contains NJATOD’s formal letter responding to proposed New Jersey Medicaid policy changes affecting Opioid Treatment Programs (OTPs).

his resource is the March 2021 New Jersey Medicaid Newsletter. It highlights program announcements, policy updates, operational guidance, and other Medicaid-related information that may affect provider billing, compliance, and service delivery in New Jersey.

This resource provides answers to frequently asked questions regarding New Jersey Medicaid’s drug testing policies, including application to provider requirements, clinical practice, billing, and compliance for Opioid Treatment Programs and other Medicaid-participating providers.

NJATOD outlines urgent concerns regarding Medicaid Alert MA-2026-03 and its impact on Opioid Treatment Programs (OTPs), including provider enrollment, reimbursement delays, and continuity of patient care.

NJATOD’s advocacy letter requesting immediate consideration of Assembly Bill A4852 to protect uninterrupted access to medication for opioid use disorder...

NJATOD’s advocacy letter outlining critical operational readiness concerns surrounding New Jersey’s planned transition of substance use disorder laboratory services into...

NJATOD’s advocacy petition requesting clarification from the New Jersey Department of Health regarding counseling documentation expectations for Opioid Treatment Programs...

NJATOD’s advocacy letter urging the New Jersey Senate Health, Human Services and Senior Citizens Committee to immediately consider Senate Bill...